In patients with non-small-cell lung carcinoma (NSCLC), the analysis of BRAF V600E mutation has become more and more applied since the introduction of many mutation-targeted medications. In this regard, the advantage of immunohistochemistry (IHC) as a reliable diagnostic test substitute to other molecular studies has not been approved yet. Objective. To examine the dependability of using immunohistochemical method utilizing monoclonal VE1 antibody in the detection of BRAF V600 E mutation in patients with non-small-cell lung carcinoma and compare the results there with that of polymerase chain reaction (SSCP-PCR). Materials and Methods. We retrospectively identified 53 patients of whom their histopathological diagnosis was non-small-cell carcinoma of different types. Evaluation of BRAF V600E mutation was assessed using polymerase chain reaction (SSCP-PCR) and IHC using VE1 antibody. This approach was applied to all cases under the study. Results. Among the 53 NSCLC samples, only 5 (9.3%) cases harbored BRAF V600E mutation, 80% were of adenocarcinoma type, and the rest (20%) was of squamous cell carcinoma. IHC analysis for VE1 was positive in 4 out of 5 (80%) BRAF-mutated tumors and negative in all nonmutated BRAF V600 E NSCLC. Conclusion. Our results revealed that VE1 antibody IHC analysis is a promising technique that can be used to detect BRAF V600-mutated NSCLC with relatively high specificity and sensitivity and might become a potential alternative to the current molecular biological methods that are in use for this purpose.

中文翻译：

---

使用单克隆VE1抗体进行的免疫组织化学研究可以代替非小细胞肺癌患者对BRAF V600E突变的理解的分子检测。

在非小细胞肺癌（NSCLC）患者中，自从引入许多靶向突变的药物以来，BRAF V600E突变的分析已变得越来越有用。在这方面，免疫组织化学（IHC）作为其他分子研究的可靠诊断测试替代品的优势尚未得到认可。目的。为了检验使用单克隆VE1抗体的免疫组织化学方法检测非小细胞肺癌患者BRAF V600 E突变的可靠性，并将其结果与聚合酶链反应（SSCP-PCR）进行比较。材料和方法。我们回顾性地确定了53例其组织病理学诊断为不同类型的非小细胞癌的患者。使用聚合酶链反应（SSCP-PCR）和使用VE1抗体的IHC对BRAF V600E突变进行评估。该方法适用于研究中的所有案例。结果。在53例NSCLC样本中，只有5例（9.3％）具有BRAF V600E突变，其中80％为腺癌类型，其余（20％）为鳞状细胞癌。在5个（80％）BRAF突变的肿瘤中，有4个（80％）的VE1的IHC分析为阳性，而在所有未突变的BRAF V600 E NSCLC中，IHC分析均为阴性。结论。我们的结果表明，VE1抗体的IHC分析是一种很有前途的技术，可用于以相对较高的特异性和敏感性检测BRAF V600突变的NSCLC，并且可能成为目前用于此目的的分子生物学方法的潜在替代方法。